Causes of Low Alkaline Phosphatase

Low alkaline phosphatase is most commonly caused by hypophosphatasia—a genetic disorder due to ALPL gene mutations—though secondary causes including malnutrition, zinc/magnesium deficiency, hypothyroidism, pernicious anemia, and antiresorptive medications (bisphosphonates, denosumab) must be systematically excluded. 1, 2

Primary Genetic Cause: Hypophosphatasia

Pathophysiology and Prevalence

Hypophosphatasia results from loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), with over 260 pathogenic variants identified. 3
Among adults with unexplained persistently low ALP, approximately 50% carry ALPL mutations, most commonly heterozygous missense variants predicted to impair enzyme activity. 4
In osteoporosis clinic populations, hypophosphatasia accounts for 3% of patients with documented low ALP (defined as <30 IU/L), though only 0.3% of all osteoporosis clinic attendees carry this diagnosis. 5

Clinical Manifestations in Adults

Adult-onset hypophosphatasia typically presents with milder manifestations than pediatric forms, including skeletal pain, chondrocalcinosis, calcific periarthritis, premature tooth loss (particularly before age 5), stress fractures, and pseudofractures. 1, 2, 3
In one cohort, 48% of ALPL mutation carriers experienced premature tooth loss versus 12% of non-carriers (p=0.04). 4
Many affected adults report only minor musculoskeletal complaints without major health problems, making the condition easily overlooked. 4

Biochemical Hallmarks

Serum ALP levels are inversely correlated with substrate accumulation: pyridoxal phosphate (PLP; r=-0.51, p=0.001), urine phosphoethanolamine (PEA; r=-0.49, p=0.001), and serum calcium (r=-0.38, p=0.012). 4
Approximately 24% of adults with low ALP have PLP levels above the reference range, and all such individuals in one study carried an ALPL mutation. 4
Mild hyperphosphatemia occurs in roughly 21% of cases (9/42 patients), and mild hypercalcemia in 7% (3/42 patients). 4

Secondary (Acquired) Causes

Nutritional and Metabolic Deficiencies

Malnutrition, particularly protein-energy malnutrition, reduces ALP synthesis. 2
Zinc deficiency impairs ALP activity, as zinc is an essential cofactor for the enzyme. 2
Magnesium deficiency similarly decreases ALP levels through cofactor depletion. 2
Vitamin C deficiency (scurvy) can lower ALP due to impaired osteoblast function. 2

Endocrine Disorders

Hypothyroidism reduces bone turnover and consequently lowers bone-derived ALP. 2
Pernicious anemia (vitamin B12 deficiency) is associated with low ALP, though the mechanism remains incompletely understood. 2

Medication-Induced Low ALP

Bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab suppress osteoclast activity, secondarily reducing osteoblast-derived ALP. 6, 2, 5
This effect is dose-dependent and reversible upon drug discontinuation, typically normalizing within months. 6
Antiresorptive therapy may mask or worsen underlying hypophosphatasia, making it critical to measure ALP before initiating treatment in patients with fragility fractures. 5

Acute Severe Illness

Low ALP is an epiphenomenon of many severe acute injuries and diseases, including sepsis, massive transfusion, cardiac surgery, and critical illness, reflecting systemic metabolic derangement rather than primary ALP deficiency. 2

Special Clinical Context: Wilson Disease

Acute Liver Failure Presentation

In acute liver failure due to Wilson disease, markedly subnormal serum ALP (typically <40 IU/L) is characteristic, occurring alongside Coombs-negative hemolytic anemia, modest aminotransferase elevations (<2000 IU/L), and coagulopathy. 1
An alkaline phosphatase-to-total bilirubin ratio <2 strongly suggests Wilson disease in this setting and should prompt urgent liver transplantation evaluation. 1
This pattern reflects massive hepatocyte necrosis with release of copper, which directly inhibits ALP activity. 1

Diagnostic Approach Algorithm

Step 1: Confirm Persistent Low ALP

Repeat ALP measurement on at least two separate occasions to exclude transient laboratory error or acute illness-related suppression. 2, 7
Define low ALP as <40 IU/L in adults, though some osteoporosis guidelines use <30 IU/L as the threshold for hypophosphatasia screening. 1, 5

Step 2: Exclude Secondary Causes

Medication review: Document all antiresorptive agents (bisphosphonates, denosumab), corticosteroids, and other bone-active drugs. 2, 5
Nutritional assessment: Measure serum zinc, magnesium, vitamin B12, folate, and 25-hydroxyvitamin D. 2
Endocrine screening: Obtain TSH and free T4 to exclude hypothyroidism. 2
Acute illness context: Review for recent surgery, sepsis, transfusion, or critical illness. 2

Step 3: Measure ALP Substrates (If Hypophosphatasia Suspected)

Pyridoxal phosphate (PLP): Elevated levels (>200 nmol/L) strongly suggest TNSALP deficiency, as PLP is a direct substrate. 4, 2
Urine phosphoethanolamine (PEA): Increased excretion (>50 µmol/mmol creatinine) supports enzyme deficiency. 4, 2
Serum inorganic pyrophosphate: Elevated levels indicate impaired ALP-mediated hydrolysis, though this assay is not widely available. 2
Substrate accumulation occurs in approximately 50% of adults with low ALP and ALPL mutations, making these tests useful but not perfectly sensitive. 4

Step 4: Genetic Testing

Sequence all coding exons and splice junctions of ALPL in patients with persistently low ALP and no identified secondary cause. 2
Recognize that approximately 50% of patients with unexplained low ALP will have negative genetic testing, possibly due to unidentified mutations in regulatory regions, epigenetic changes, or abnormalities in other genes. 2
Heterozygous ALPL mutations are the most common finding (present in 86% of mutation-positive cases), and most are missense variants predicted to have damaging effects on protein activity. 4

Step 5: Clinical Phenotyping

Dental history: Inquire about premature tooth loss (especially primary teeth before age 5), which occurs in nearly half of ALPL mutation carriers. 4
Skeletal symptoms: Assess for chronic bone pain, stress fractures, pseudofractures, chondrocalcinosis, and calcific periarthritis. 2, 3
Fracture history: Review for atypical femoral fractures, which occurred in 2/22 patients (9%) in one osteoporosis cohort. 5
Family history: Obtain three-generation pedigree, as hypophosphatasia follows autosomal recessive (severe forms) or autosomal dominant (mild forms) inheritance. 3

Critical Pitfalls to Avoid

Do not assume low ALP is benign or laboratory error without confirming persistence and excluding secondary causes; approximately 9% of osteoporosis clinic patients have at least one low ALP measurement. 5
Do not initiate bisphosphonates or denosumab in patients with unexplained low ALP without first ruling out hypophosphatasia, as antiresorptive therapy is relatively contraindicated and may worsen skeletal outcomes. 5
Do not rely solely on genetic testing to exclude hypophosphatasia; substrate measurements (PLP, PEA) provide functional evidence of enzyme deficiency even when ALPL sequencing is negative. 2
Do not overlook Wilson disease in young adults (<40 years) presenting with acute liver failure and low ALP; the alkaline phosphatase-to-bilirubin ratio <2 is a critical diagnostic clue requiring urgent transplant evaluation. 1
Do not dismiss mild symptoms (musculoskeletal pain, dental problems) in patients with persistently low ALP and substrate accumulation, as these may represent subclinical hypophosphatasia with long-term skeletal consequences. 4

Prevalence Context

In hospital-wide laboratory databases, low ALP (<40 IU/L) occurs in approximately 0.6% of all patients, though most cases are transient or secondary to acute illness. 7, 5
Among patients with at least two documented low ALP measurements, secondary causes can be identified in the majority (398/410 patients, or 97%, in one cohort), leaving only 3% with unexplained persistent hypophosphatasemia. 7
In osteoporosis clinic populations, 9% have at least one low ALP, 2.7% have low ALP on multiple occasions, and 0.4% have persistently low levels. 5

Monitoring and Follow-Up

For patients with confirmed hypophosphatasia, avoid antiresorptive therapy and consider referral to a metabolic bone specialist for enzyme replacement therapy (asfotase alfa) if symptomatic. 5, 3
For patients with secondary causes, repeat ALP after addressing the underlying condition (e.g., 3–6 months after zinc/magnesium repletion or bisphosphonate discontinuation). 2
For patients with unexplained persistent low ALP and negative genetic testing, monitor substrate levels (PLP, PEA) annually and reassess for evolving symptoms, as unidentified genetic or epigenetic mechanisms may be present. 2

What are the causes of low alkaline phosphatase?

Help us tailor your experience